Roche to add HIV blindness drug to Patent Pool
This article was originally published in Scrip
Executive Summary
Roche is slashing the price of valganciclovir, which treates cytomegalovirus (CMV) – a viral infection that can cause retinitis (blindness) in people with HIV – by up to 90% in developing countries under a new agreement with the Medicines Patent Pool.